Topic Review
Ubiquitylation
Ubiquitylation is a post-translational modification that covalently conjugates the ubiquitin molecule through the C-terminus to a lysine residue on a substrate protein. Ubiquitylation results in the turnover of the ubiquitylated substrate protein by either the proteasome or lysosome, a change in subcellular localization of the substrate protein, or alteration of substrate protein function . Ubiquitylation is mediated by three enzymes and scaffolding proteins: E1, E2, and E3.
  • 658
  • 22 Jun 2021
Topic Review
Types of Transcatheter Aortic Valve Replacement Devices
Transcatheter aortic valve replacement (TAVR) was originally conceptualized in the early 1990s, largely inspired by the pioneering experiences in the field of percutaneous transluminal coronary angioplasty.
  • 5.3K
  • 03 Aug 2022
Topic Review
Types of Dysrhythmias
Dysrhythmia is a term referring to the occurrence of spontaneous and repetitive changes in potentials with parameters deviating from those considered normal. The term refers to heart anomalies but has a broader meaning. Dysrhythmias may concern the heart, neurological system, digestive system, and sensory organs. Ion currents conducted through ion channels are a universal phenomenon. The occurrence of channel abnormalities will therefore result in disorders with clinical manifestations depending on the affected tissue, but phenomena from other tissues and organs may also manifest themselves. 
  • 168
  • 04 Jan 2024
Topic Review
TXNIP
Thioredoxin interacting protein (TXNIP) is a metabolism- oxidative- and inflammation-related marker induced in cardiovascular diseases and is believed to represent a possible link between metabolism and cellular redox status. TXNIP is a potential biomarker in cardiovascular and ischemic diseases but also a novel identified target for preventive and curative medicine. 
  • 432
  • 12 Apr 2021
Topic Review
Tryptophan Metabolism in Cardiovascular Diseases
Cardiovascular disease (CVD) is one of the major causes of mortality worldwide. Inflammation is the underlying common mechanism involved in CVD. It has been recently related to amino acid metabolism, which acts as a critical regulator of innate and adaptive immune responses. Among different metabolites that have emerged as important regulators of immune and inflammatory responses, tryptophan (Trp) metabolites have been shown to play a pivotal role in CVD.
  • 962
  • 13 Oct 2021
Topic Review
Triglyceride/High-Density Lipoprotein Cholesterol Ratio in Metabolic Syndrome
Increased plasma triglycerides (TG) and decreased high-density lipoprotein cholesterol (HDL-C) levels have been associated with metabolic syndrome (MetS) and cardiovascular disease (CVD), and their ratio, TG/HDL-C, has been proposed as a novel biomarker for predicting the risk of both clinical entities.
  • 295
  • 17 Mar 2023
Topic Review
Tricuspid Atresia
Tricuspid atresia (TA) is a cyanotic, congenital heart defect (CHD) and is defined as congenital absence or agenesis of the morphologic tricuspid valve. It is the third most common cyanotic CHD, and is the most common cause of cyanosis with left ventricular hypertrophy. The prevalence of TA is estimated to be 2.9% of autopsy cases and 1.4% to 1.5% of the clinical cases of CHD.
  • 2.3K
  • 20 Oct 2021
Topic Review
Treatment of Transthyretin Amyloid Cardiomyopathy
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressively debilitating, rare disease associated with high mortality. ATTR-CM occurs when TTR amyloid protein builds up in the myocardium along with different organs, most commonly the peripheral and the autonomic nervous systems. Managing the cardiac complications with standard heart failure medications is difficult due to the challenge to maintain a balance between the high filling pressure associated with restricted ventricular volume and the low cardiac output. To date, tafamidis is the only agent approved for ATTR-CM treatment.
  • 489
  • 06 May 2022
Topic Review
Treatment of Obstructive Hypertrophic Cardiomyopathy
Left ventricular outflow obstruction (LVOTO) and diastolic dysfunction are the main pathophysiological characteristics of hypertrophic cardiomyopathy (HCM)LVOTO, may be identified in more than half of HCM patients and represents an important determinant of symptoms and a predictor of worse prognosis.  Treatment of LVOTO is indicated in patients with lifestyle-limiting symptoms only. Negative inotropic and chronotropic medications are indicated as the first-line therapy. If patients remain symptomatic, or remain in the presence of side effects, surgery is suggested only when performed in experienced centers.
  • 224
  • 30 May 2023
Topic Review
Treatment of IgA Nephropathy
IgA nephropathy remains the most common primary glomerular disease worldwide. It affects children and adults of all ages, and is a leading cause of end-stage kidney disease, making it a considerable public health issue in many countries.
  • 385
  • 21 Jun 2021
  • Page
  • of
  • 89